Medical/Pharmaceuticals

Avid Organics to Launch the World's First Commercial-Scale Bio-Based Glycolic Acid, AviGa™ Bio HP70, at in-cosmetics® Global in Paris

* AviGa™ Bio HP70 is a bio-based, 70% cosmetic-grade glycolic acid available globally from April 14, 2026, with REACH registration ensuring uninterrupted European supply * The launch marks a pivotal shift for personal care, cosmetics, and pharmaceutical industries by offering a sustainable, t...

2026-03-18 17:27 823

Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics

* The Atlas will expand known evolutionary genetic diversity by 100x, collecting novel genomic data from over 100 million new species across thousands of sites globally. * By partnering with Anthropic, Ultima Genomics, and PacBio, and powered by NVIDIA AI infrastructure, Basecamp Research aim...

2026-03-18 17:00 536

ProtectHealth strengthen PeKa b40 health screening promotion with Hospital Shah Alam staff in Program Ziarah MADANI

SHAH ALAM, Malaysia, March 18, 2026 /PRNewswire/ -- ProtectHealth Corporation Sdn. Bhd., as an implementing agency under the Ministry of Health Malaysia (MOH), continues to strengthen efforts to promote the Skim Peduli Kesihatan for the B40 group during the Program Ziarah MADANI at Hospital Shah ...

2026-03-18 14:26 1231

Innodisk at NVIDIA GTC 2026: Accelerating Real-World AI for Healthcare and Mobility with Full-Stack Edge Solutions

SAN JOSE, Calif., March 18, 2026 /PRNewswire/ -- Innodisk, a leading global AI solution provider, today announced its participation in NVIDIA GTC 2026. Alongside subsidiary Aetina, Innodisk Group is showcasing the seamless integration of NVIDIA AI architectures into scalable, deployable edge AI ...

2026-03-18 11:32 1981

Everest Medicines Enters into Letter of Intent with Hasten Biopharmaceuticals (Asia) Limited

SHANGHAI, March 18, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a letter of...

2026-03-18 11:07 1879

North London Collegiate School (Singapore) Student Achieves Academic Milestone with Peer-Reviewed Journal Publication

Saket Subramaniam of North London Collegiate School (Singapore) publishes peer-reviewed medical research on colorectal cancer liver metastasis in the American Journal of Student Research. SINGAPORE, March 18, 2026 /PRNewswire/ -- North London Collegiate School (Singapore) celebrates the remarkab...

2026-03-18 10:00 2338

Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs

SHANGHAI and HONG KONG, March 18, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune ...

2026-03-18 08:30 2620

Vieworks to Debut VISQUE DPS LH210 at USCAP 2026, a Single Scanner for Both Cytology and Histology

High-throughput, mid capacity LH210 expands the VISQUE DPS lineup with fast scanning, optimized data size, and scalable digital pathology workflow ANYANG, South Korea, March 18, 2026 /PRNewswire/ -- Vieworks, a global provider of advanced imaging solutions, will participate inUSCAP 2026 (United ...

2026-03-18 07:30 1683

Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases

IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA–LNP platform. HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinical‑st...

2026-03-17 21:30 1986

Metabolon Collaborates with The Michael J. Fox Foundation to Advance Multiomic Analyses for Parkinson's Research

Partnership supports expanded biomarker discovery efforts within MJFF's Parkinson's Progression Markers Initiative MORRISVILLE, N.C., March 17, 2026 /PRNewswire/ -- Metabolon , ...

2026-03-17 21:00 2046

Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therap...

2026-03-17 20:00 1476

Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models

- In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide. EC50  for human amylin 1 receptor (hAMY1R) was 21.4 pM and 21.2 pM for ASC39 and elo...

2026-03-17 18:00 1911

/C O R R E C T I O N -- Gesynta Pharma/

In the news release, First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat, issued 11-Mar-2026 by Gesynta Pharma over PR Newswire, the source was erroneously mentioned as Getinge Group rather than as Gesynta Pharma as incorrectly transmitted by PR Newswire. The complete, cor...

2026-03-17 17:24 4366

Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference

SUZHOU, China and MÖLNDALS, Sweden, March 17, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd.  ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleo...

2026-03-17 11:00 2325

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027

SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) tar...

2026-03-17 10:32 2785

Dr Cho Li Wei of LW Cho Endocrine Clinic Marks 27 Years of Clinical Practice and Multilingual Care

SINGAPORE, March 17, 2026 /PRNewswire/ -- Dr Cho Li Wei, leading LW Cho Endocrine Clinic, is marking 23 years in endocrinology and 27 years in clinical practice, with a continued focus on bridging language gaps in specialist medical care. The clinic serves patients across conditions including dia...

2026-03-17 10:10 2288

BioCina Initiates Comprehensive Manufacturing Program for Patrys' Proprietary Injectable Therapeutic to Alleviate Delirium

PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd ., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a c...

2026-03-17 09:05 1561

Field Medical Names Mark A. Turco, MD, as Chief Executive Officer

CARDIFF-BY-THE-SEA, Calif., March 16, 2026 /PRNewswire/ -- Field Medical, Inc ., a clinical-stage medical technology company advancing second-generation pulsed f...

2026-03-16 21:38 1419

GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth

Group Performance * Revenue: US$959.5 million, +61.4% year-on-year * Gross profit: US$553.2 million, +103.3% year-on-year * Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Performance * GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year ...

2026-03-16 18:54 2857

Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call

SHANGHAI, March 16, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial re...

2026-03-16 17:58 1825
12345 ... 393

Week's Top Stories